These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 18688916)

  • 1. Short-term influence of adalimumab on work productivity outcomes in patients with rheumatoid arthritis.
    Zhang W; Bansback N; Guh D; Li X; Nosyk B; Marra CA; Anis AH
    J Rheumatol; 2008 Sep; 35(9):1729-36. PubMed ID: 18688916
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of etanercept on work and activity impairment in employed moderate to severe rheumatoid arthritis patients in the United States.
    Hone D; Cheng A; Watson C; Huang B; Bitman B; Huang XY; Gandra SR
    Arthritis Care Res (Hoboken); 2013 Oct; 65(10):1564-72. PubMed ID: 23554320
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improvement in work place and household productivity for patients with early rheumatoid arthritis treated with adalimumab plus methotrexate: work outcomes and their correlations with clinical and radiographic measures from a randomized controlled trial companion study.
    van Vollenhoven RF; Cifaldi MA; Ray S; Chen N; Weisman MH
    Arthritis Care Res (Hoboken); 2010 Feb; 62(2):226-34. PubMed ID: 20191522
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).
    Furst DE; Schiff MH; Fleischmann RM; Strand V; Birbara CA; Compagnone D; Fischkoff SA; Chartash EK
    J Rheumatol; 2003 Dec; 30(12):2563-71. PubMed ID: 14719195
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of age, sex, physical function, health-related quality of life, and treatment with adalimumab on work status and work productivity of patients with ankylosing spondylitis.
    Maksymowych WP; Gooch KL; Wong RL; Kupper H; van der Heijde D
    J Rheumatol; 2010 Feb; 37(2):385-92. PubMed ID: 19955052
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of adalimumab treatment and psoriasis severity on self-reported work productivity and activity impairment for patients with moderate to severe psoriasis.
    Kimball AB; Yu AP; Signorovitch J; Xie J; Tsaneva M; Gupta SR; Bao Y; Mulani PM
    J Am Acad Dermatol; 2012 Feb; 66(2):e67-76. PubMed ID: 21616560
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of the Stanford Health Assessment Questionnaire in estimation of long-term productivity costs in patients with recent-onset rheumatoid arthritis.
    Puolakka K; Kautiainen H; Mottonen T; Hannonen P; Korpela M; Hakala M; Luukkainen R; Vuori K; Blåfield H; Leirisalo-Repo M
    Scand J Rheumatol; 2009; 38(2):96-103. PubMed ID: 19274516
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice.
    Bombardieri S; Ruiz AA; Fardellone P; Geusens P; McKenna F; Unnebrink K; Oezer U; Kary S; Kupper H; Burmester GR;
    Rheumatology (Oxford); 2007 Jul; 46(7):1191-9. PubMed ID: 17504821
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of adalimumab on work participation in rheumatoid arthritis: comparison of an open-label extension study and a registry-based control group.
    Halpern MT; Cifaldi MA; Kvien TK
    Ann Rheum Dis; 2009 Jun; 68(6):930-7. PubMed ID: 18829616
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Responses to adalimumab in patients with active psoriatic arthritis who have not adequately responded to prior therapy: effectiveness and safety results from an open-label study.
    Gladman DD; ; Sampalis JS; Illouz O; Guérette B
    J Rheumatol; 2010 Sep; 37(9):1898-906. PubMed ID: 20595284
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial.
    Burmester GR; Mariette X; Montecucco C; Monteagudo-Sáez I; Malaise M; Tzioufas AG; Bijlsma JW; Unnebrink K; Kary S; Kupper H
    Ann Rheum Dis; 2007 Jun; 66(6):732-9. PubMed ID: 17329305
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adalimumab plus methotrexate improved SF-36 scores and reduced the effect of rheumatoid arthritis (RA) on work activity for patients with early RA.
    Kimel M; Cifaldi M; Chen N; Revicki D
    J Rheumatol; 2008 Feb; 35(2):206-15. PubMed ID: 18085743
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry.
    Hetland ML; Christensen IJ; Tarp U; Dreyer L; Hansen A; Hansen IT; Kollerup G; Linde L; Lindegaard HM; Poulsen UE; Schlemmer A; Jensen DV; Jensen S; Hostenkamp G; Østergaard M;
    Arthritis Rheum; 2010 Jan; 62(1):22-32. PubMed ID: 20039405
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Work limitations among working persons with rheumatoid arthritis: results, reliability, and validity of the work limitations questionnaire in 836 patients.
    Walker N; Michaud K; Wolfe F
    J Rheumatol; 2005 Jun; 32(6):1006-12. PubMed ID: 15940759
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discriminant validity, responsiveness and reliability of the rheumatoid arthritis-specific Work Productivity Survey (WPS-RA).
    Osterhaus JT; Purcaru O; Richard L
    Arthritis Res Ther; 2009; 11(3):R73. PubMed ID: 19457255
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved health-related quality of life for patients with active rheumatoid arthritis receiving rituximab: Results of the Dose-Ranging Assessment: International Clinical Evaluation of Rituximab in Rheumatoid Arthritis (DANCER) Trial.
    Mease PJ; Revicki DA; Szechinski J; Greenwald M; Kivitz A; Barile-Fabris L; Kalsi J; Eames J; Leirisalo-Repo M
    J Rheumatol; 2008 Jan; 35(1):20-30. PubMed ID: 18050385
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-world anti-tumor necrosis factor treatment in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: cost-effectiveness based on number needed to treat to improve health assessment questionnaire.
    Barra L; Pope JE; Payne M
    J Rheumatol; 2009 Jul; 36(7):1421-8. PubMed ID: 19487267
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Productivity loss due to absenteeism and presenteeism by different instruments in patients with RA and subjects without RA.
    Braakman-Jansen LM; Taal E; Kuper IH; van de Laar MA
    Rheumatology (Oxford); 2012 Feb; 51(2):354-61. PubMed ID: 22179729
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Physical function and health related quality of life: analysis of 2-year data from randomized, controlled studies of leflunomide, sulfasalazine, or methotrexate in patients with active rheumatoid arthritis.
    Strand V; Scott DL; Emery P; Kalden JR; Smolen JS; Cannon GW; Tugwell P; Crawford B;
    J Rheumatol; 2005 Apr; 32(4):590-601. PubMed ID: 15801012
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors associated with absenteeism, presenteeism and activity impairment in patients in the first years of RA.
    Bansback N; Zhang W; Walsh D; Kiely P; Williams R; Guh D; Anis A; Young A
    Rheumatology (Oxford); 2012 Feb; 51(2):375-84. PubMed ID: 22179728
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.